,address1,city,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,Zernikedreef 9,Leiden,2333 CK,Netherlands,31 88 166 7000,https://www.proqr.com,Biotechnology,Healthcare,"ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; AX-9115 for rare metabolic condition; and AX-2402 for rare neurodegenerative conditions, as well as other targets in its discovery pipeline. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.",130,"{'maxAge': 1, 'name': 'Dr. Domenico  Valerio Ph.D.', 'age': 66, 'title': 'Founder & Independent Chairman of Supervisory Board', 'yearBorn': 1956, 'fiscalYear': 2022, 'totalPay': 78972, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.61,1.59,1.59,1.6311,1.61,1.59,1.59,1.6311,0.0,-0.019709,-3.744186,64051,64051,199014,114230,114230,1.6,1.65,3100,1400,130313080,0.722,3.85,29.07476,1.5928,2.195575,0.0,0.0,USD,22990098,0.0,62815769,80939800,940887,1158568,1690761600,1693440000,0.0116,0.19176,0.38973,4.99,0.015,0.64,2.515625,1672444800,1703980800,1688083200,-54229000,-0.79,-0.43,5.129,-0.467,NCM,EQUITY,PRQR,PRQR,ProQR Therapeutics N.V.,ProQR Therapeutics N.V.,1411047000,America/New_York,EDT,-14400000,1.61,5.94,1.98,3.91,4.71,2.2,buy,8,128562000,1.588,-49274000,21529000,5.613,5.708,4482000,41.804,0.059,-0.19126,-0.78172,4802000,-27780124,1181000,0.208,1.0,0.0,-11.1646595,EUR,
1,Zernikedreef 9,Leiden,2333 CK,Netherlands,31 88 166 7000,https://www.proqr.com,Biotechnology,Healthcare,"ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; AX-9115 for rare metabolic condition; and AX-2402 for rare neurodegenerative conditions, as well as other targets in its discovery pipeline. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.",130,"{'maxAge': 1, 'name': 'Mr. Daniel Anton de Boer', 'age': 39, 'title': 'Founder, CEO & Member of Management Board', 'yearBorn': 1983, 'fiscalYear': 2022, 'totalPay': 1407636, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.61,1.59,1.59,1.6311,1.61,1.59,1.59,1.6311,0.0,-0.019709,-3.744186,64051,64051,199014,114230,114230,1.6,1.65,3100,1400,130313080,0.722,3.85,29.07476,1.5928,2.195575,0.0,0.0,USD,22990098,0.0,62815769,80939800,940887,1158568,1690761600,1693440000,0.0116,0.19176,0.38973,4.99,0.015,0.64,2.515625,1672444800,1703980800,1688083200,-54229000,-0.79,-0.43,5.129,-0.467,NCM,EQUITY,PRQR,PRQR,ProQR Therapeutics N.V.,ProQR Therapeutics N.V.,1411047000,America/New_York,EDT,-14400000,1.61,5.94,1.98,3.91,4.71,2.2,buy,8,128562000,1.588,-49274000,21529000,5.613,5.708,4482000,41.804,0.059,-0.19126,-0.78172,4802000,-27780124,1181000,0.208,1.0,0.0,-11.1646595,EUR,
2,Zernikedreef 9,Leiden,2333 CK,Netherlands,31 88 166 7000,https://www.proqr.com,Biotechnology,Healthcare,"ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; AX-9115 for rare metabolic condition; and AX-2402 for rare neurodegenerative conditions, as well as other targets in its discovery pipeline. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.",130,"{'maxAge': 1, 'name': 'Mr. Rene K. Beukema', 'age': 58, 'title': 'Chief Corp. Devel. Officer, Gen. Counsel & Member of Management Board', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 313756, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.61,1.59,1.59,1.6311,1.61,1.59,1.59,1.6311,0.0,-0.019709,-3.744186,64051,64051,199014,114230,114230,1.6,1.65,3100,1400,130313080,0.722,3.85,29.07476,1.5928,2.195575,0.0,0.0,USD,22990098,0.0,62815769,80939800,940887,1158568,1690761600,1693440000,0.0116,0.19176,0.38973,4.99,0.015,0.64,2.515625,1672444800,1703980800,1688083200,-54229000,-0.79,-0.43,5.129,-0.467,NCM,EQUITY,PRQR,PRQR,ProQR Therapeutics N.V.,ProQR Therapeutics N.V.,1411047000,America/New_York,EDT,-14400000,1.61,5.94,1.98,3.91,4.71,2.2,buy,8,128562000,1.588,-49274000,21529000,5.613,5.708,4482000,41.804,0.059,-0.19126,-0.78172,4802000,-27780124,1181000,0.208,1.0,0.0,-11.1646595,EUR,
3,Zernikedreef 9,Leiden,2333 CK,Netherlands,31 88 166 7000,https://www.proqr.com,Biotechnology,Healthcare,"ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; AX-9115 for rare metabolic condition; and AX-2402 for rare neurodegenerative conditions, as well as other targets in its discovery pipeline. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.",130,"{'maxAge': 1, 'name': 'Dr. Gerard  Platenburg', 'age': 58, 'title': 'Co-Founder & Chief Scientific Officer', 'yearBorn': 1964, 'fiscalYear': 2013, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.61,1.59,1.59,1.6311,1.61,1.59,1.59,1.6311,0.0,-0.019709,-3.744186,64051,64051,199014,114230,114230,1.6,1.65,3100,1400,130313080,0.722,3.85,29.07476,1.5928,2.195575,0.0,0.0,USD,22990098,0.0,62815769,80939800,940887,1158568,1690761600,1693440000,0.0116,0.19176,0.38973,4.99,0.015,0.64,2.515625,1672444800,1703980800,1688083200,-54229000,-0.79,-0.43,5.129,-0.467,NCM,EQUITY,PRQR,PRQR,ProQR Therapeutics N.V.,ProQR Therapeutics N.V.,1411047000,America/New_York,EDT,-14400000,1.61,5.94,1.98,3.91,4.71,2.2,buy,8,128562000,1.588,-49274000,21529000,5.613,5.708,4482000,41.804,0.059,-0.19126,-0.78172,4802000,-27780124,1181000,0.208,1.0,0.0,-11.1646595,EUR,
4,Zernikedreef 9,Leiden,2333 CK,Netherlands,31 88 166 7000,https://www.proqr.com,Biotechnology,Healthcare,"ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; AX-9115 for rare metabolic condition; and AX-2402 for rare neurodegenerative conditions, as well as other targets in its discovery pipeline. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.",130,"{'maxAge': 1, 'name': 'Mr. Jurriaan  Dekkers', 'age': 46, 'title': 'Chief Financial Officer', 'yearBorn': 1976, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.61,1.59,1.59,1.6311,1.61,1.59,1.59,1.6311,0.0,-0.019709,-3.744186,64051,64051,199014,114230,114230,1.6,1.65,3100,1400,130313080,0.722,3.85,29.07476,1.5928,2.195575,0.0,0.0,USD,22990098,0.0,62815769,80939800,940887,1158568,1690761600,1693440000,0.0116,0.19176,0.38973,4.99,0.015,0.64,2.515625,1672444800,1703980800,1688083200,-54229000,-0.79,-0.43,5.129,-0.467,NCM,EQUITY,PRQR,PRQR,ProQR Therapeutics N.V.,ProQR Therapeutics N.V.,1411047000,America/New_York,EDT,-14400000,1.61,5.94,1.98,3.91,4.71,2.2,buy,8,128562000,1.588,-49274000,21529000,5.613,5.708,4482000,41.804,0.059,-0.19126,-0.78172,4802000,-27780124,1181000,0.208,1.0,0.0,-11.1646595,EUR,
5,Zernikedreef 9,Leiden,2333 CK,Netherlands,31 88 166 7000,https://www.proqr.com,Biotechnology,Healthcare,"ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; AX-9115 for rare metabolic condition; and AX-2402 for rare neurodegenerative conditions, as well as other targets in its discovery pipeline. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.",130,"{'maxAge': 1, 'name': 'Ms. Sheila  Sponselee', 'age': 38, 'title': 'VP & Head of People and Operations', 'yearBorn': 1984, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.61,1.59,1.59,1.6311,1.61,1.59,1.59,1.6311,0.0,-0.019709,-3.744186,64051,64051,199014,114230,114230,1.6,1.65,3100,1400,130313080,0.722,3.85,29.07476,1.5928,2.195575,0.0,0.0,USD,22990098,0.0,62815769,80939800,940887,1158568,1690761600,1693440000,0.0116,0.19176,0.38973,4.99,0.015,0.64,2.515625,1672444800,1703980800,1688083200,-54229000,-0.79,-0.43,5.129,-0.467,NCM,EQUITY,PRQR,PRQR,ProQR Therapeutics N.V.,ProQR Therapeutics N.V.,1411047000,America/New_York,EDT,-14400000,1.61,5.94,1.98,3.91,4.71,2.2,buy,8,128562000,1.588,-49274000,21529000,5.613,5.708,4482000,41.804,0.059,-0.19126,-0.78172,4802000,-27780124,1181000,0.208,1.0,0.0,-11.1646595,EUR,
6,Zernikedreef 9,Leiden,2333 CK,Netherlands,31 88 166 7000,https://www.proqr.com,Biotechnology,Healthcare,"ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; AX-9115 for rare metabolic condition; and AX-2402 for rare neurodegenerative conditions, as well as other targets in its discovery pipeline. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.",130,"{'maxAge': 1, 'name': 'Ms. Sarah Cue Kiely', 'title': 'VP of Investor Relations & Corp. Communications', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.61,1.59,1.59,1.6311,1.61,1.59,1.59,1.6311,0.0,-0.019709,-3.744186,64051,64051,199014,114230,114230,1.6,1.65,3100,1400,130313080,0.722,3.85,29.07476,1.5928,2.195575,0.0,0.0,USD,22990098,0.0,62815769,80939800,940887,1158568,1690761600,1693440000,0.0116,0.19176,0.38973,4.99,0.015,0.64,2.515625,1672444800,1703980800,1688083200,-54229000,-0.79,-0.43,5.129,-0.467,NCM,EQUITY,PRQR,PRQR,ProQR Therapeutics N.V.,ProQR Therapeutics N.V.,1411047000,America/New_York,EDT,-14400000,1.61,5.94,1.98,3.91,4.71,2.2,buy,8,128562000,1.588,-49274000,21529000,5.613,5.708,4482000,41.804,0.059,-0.19126,-0.78172,4802000,-27780124,1181000,0.208,1.0,0.0,-11.1646595,EUR,
7,Zernikedreef 9,Leiden,2333 CK,Netherlands,31 88 166 7000,https://www.proqr.com,Biotechnology,Healthcare,"ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; AX-9115 for rare metabolic condition; and AX-2402 for rare neurodegenerative conditions, as well as other targets in its discovery pipeline. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.",130,"{'maxAge': 1, 'name': 'Ms. Sandra  van der Kolk', 'title': 'Jr. Financial Controller', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.61,1.59,1.59,1.6311,1.61,1.59,1.59,1.6311,0.0,-0.019709,-3.744186,64051,64051,199014,114230,114230,1.6,1.65,3100,1400,130313080,0.722,3.85,29.07476,1.5928,2.195575,0.0,0.0,USD,22990098,0.0,62815769,80939800,940887,1158568,1690761600,1693440000,0.0116,0.19176,0.38973,4.99,0.015,0.64,2.515625,1672444800,1703980800,1688083200,-54229000,-0.79,-0.43,5.129,-0.467,NCM,EQUITY,PRQR,PRQR,ProQR Therapeutics N.V.,ProQR Therapeutics N.V.,1411047000,America/New_York,EDT,-14400000,1.61,5.94,1.98,3.91,4.71,2.2,buy,8,128562000,1.588,-49274000,21529000,5.613,5.708,4482000,41.804,0.059,-0.19126,-0.78172,4802000,-27780124,1181000,0.208,1.0,0.0,-11.1646595,EUR,
